liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Endoscopic third ventriculostomy for adults with hydrocephalus: creating a prognostic model for success: protocol for a retrospective multicentre study (Nordic ETV)
Rigshosp, Denmark.
Rigshosp, Denmark.
Karolinska Univ Hosp, Sweden.
Karolinska Univ Hosp, Sweden.
Show others and affiliations
2022 (English)In: BMJ Open, E-ISSN 2044-6055, Vol. 12, no 1, article id e055570Article in journal (Refereed) Published
Abstract [en]

Introduction Endoscopic third ventriculostomy (ETV) is becoming an increasingly widespread treatment for hydrocephalus, but research is primarily based on paediatric populations. In 2009, Kulkarni et al created the ETV Success score to predict the outcome of ETV in children. The purpose of this study is to create a prognostic model to predict the success of ETV for adult patients with hydrocephalus. The ability to predict who will benefit from an ETV will allow better primary patient selection both for EN and shunting. This would reduce additional second procedures due to primary treatment failure. A success score specific for adults could also be used as a communication tool to provide better information and guidance to patients. Methods and analysis The study will adhere to the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis reporting guidelines and conducted as a retrospective chart review of all patients >= 18 years of age treated with EN at the participating centres between 1 January 2010 and 31 December 2018. Data collection is conducted locally in a standardised database. Univariate analysis will be used to identify several strong predictors to be included in a multivariate logistic regression model. The model will be validated using K-fold cross validation. Discrimination will be assessed using area under the receiver operating characteristic curve (AUROC) and calibration with calibration belt plots. Ethics and dissemination The study is approved by appropriate ethics or patient safety boards in all participating countries.

Place, publisher, year, edition, pages
BMJ PUBLISHING GROUP , 2022. Vol. 12, no 1, article id e055570
National Category
Social and Clinical Pharmacy
Identifiers
URN: urn:nbn:se:liu:diva-183248DOI: 10.1136/bmjopen-2021-055570ISI: 000749001500058PubMedID: 35105647OAI: oai:DiVA.org:liu-183248DiVA, id: diva2:1642162
Note

Funding Agencies|Lundbeck FoundationLundbeckfonden [F-22218-19]; Hjerneog Nervekirurgisk Forskningspulje, Rigshospitalet [F23026-02, N497]

Available from: 2022-03-04 Created: 2022-03-04 Last updated: 2023-08-28

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Tobieson, Lovisa
By organisation
Division of NeurobiologyFaculty of Medicine and Health SciencesDepartment of Neurosurgery
In the same journal
BMJ Open
Social and Clinical Pharmacy

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 34 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf